Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

2.

Growth-restricted dengue virus mutants containing deletions in the 5' noncoding region of the RNA genome.

Cahour A, Pletnev A, Vazielle-Falcoz M, Rosen L, Lai CJ.

Virology. 1995 Feb 20;207(1):68-76.

3.

Evaluation of molecular strategies to develop a live dengue vaccine.

Lai CJ, Bray M, Men R, Cahour A, Chen W, Kawano H, Tadano M, Hiramatsu K, Tokimatsu I, Pletnev A, Arakai S, Shameem G, Rinaudo M.

Clin Diagn Virol. 1998 Jul 15;10(2-3):173-9.

PMID:
9741643
5.

Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys.

Markoff L, Pang X, Houng Hs HS, Falgout B, Olsen R, Jones E, Polo S.

J Virol. 2002 Apr;76(7):3318-28.

6.

Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.

Blaney JE Jr, Sathe NS, Goddard L, Hanson CT, Romero TA, Hanley KA, Murphy BR, Whitehead SS.

Vaccine. 2008 Feb 6;26(6):817-28. doi: 10.1016/j.vaccine.2007.11.082. Epub 2007 Dec 26.

7.

Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys.

Blaney JE Jr, Speicher J, Hanson CT, Sathe NS, Whitehead SS, Murphy BR, Pletnev AG.

Vaccine. 2008 Aug 5;26(33):4150-9. doi: 10.1016/j.vaccine.2008.05.075. Epub 2008 Jun 13.

8.
9.

Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses.

Pletnev AG, Bray M, Huggins J, Lai CJ.

Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10532-6.

10.

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.

Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP.

J Virol. 2000 Jun;74(12):5477-85.

11.

Dengue type four viruses with E-Glu345Lys adaptive mutation from MRC-5 cells induce low viremia but elicit potent neutralizing antibodies in rhesus monkeys.

Lin HH, Lee HC, Li XF, Tsai MJ, Hsiao HJ, Peng JG, Sue SC, Qin CF, Wu SC.

PLoS One. 2014 Jun 24;9(6):e100130. doi: 10.1371/journal.pone.0100130. eCollection 2014 Jun 24.

12.

Identification of mutations in a candidate dengue 4 vaccine strain 341750 PDK20 and construction of a full-length cDNA clone of the PDK20 vaccine candidate.

Kelly EP, Puri B, Sun W, Falgout B.

Vaccine. 2010 Apr 9;28(17):3030-7. doi: 10.1016/j.vaccine.2009.10.084. Epub 2009 Oct 27.

PMID:
19874927
14.
15.

Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys.

Rumyantsev AA, Chanock RM, Murphy BR, Pletnev AG.

Vaccine. 2006 Jan 12;24(2):133-43. Epub 2005 Aug 9.

PMID:
16115704
16.
17.

Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.

Pletnev AG, Swayne DE, Speicher J, Rumyantsev AA, Murphy BR.

Vaccine. 2006 Sep 29;24(40-41):6392-404. Epub 2006 Jun 21.

PMID:
16831498
18.

Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus.

Pletnev AG, Claire MS, Elkins R, Speicher J, Murphy BR, Chanock RM.

Virology. 2003 Sep 15;314(1):190-5.

19.

Supplemental Content

Support Center